Sponsor study identifier
observational
10,000
1 country
1
Study Start
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermined significance (MGUS), a precursor conditions to multiple myeloma. We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 30, 2023
Actual (reported)July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 28, 2023
Actual (reported)August 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The prevalence of monoclonal gammopathy of undetermined significance (MGUS) in MM first-degree relatives
The prevalence of MGUS in MM first-degree relatives: defined as the proportion of MGUS cases among the total population ( MM first-degree relatives) receiving M-protein screening
2 Years
Time to progression (TTP) from MGUS to overt multiple myeloma
The time interval between the first diagnosis of MGUS and the first recording of participants and the diagnosis of myeloma. For participants who did not record disease progression to myeloma, the last follow-up date was used as the cut-off date.
10 Years
Overall survival of MGUS patients
10 Years
Quality of life (QoL) of MGUS patients
10 Years
All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The first-degree relatives of patients with multiple myeloma in the Chinese population.
Zhongshan Hospital，Fudan University
Shanghai, Shanghai Municipality, 200032, China
Li J, Wang Y, Liu P. The impact on early diagnosis and survival outcome of M-protein screening-driven diagnostic approach to multiple myeloma in China: a cohort study. J Cancer. 2019 Aug 27;10(20):4807-4813. doi: 10.7150/jca.32103. eCollection 2019.
Peng Liu, PhD, MD
Fudan University
First Submitted
June 30, 2023
First Posted
July 28, 2023
Study Start
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 2025
Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 1, 2023
Record last verified: 2023-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: